SCHEMBL5364529

SCHEMBL5364529

CC(C)c1ccc2c(ncn2C)c1C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.40
DPP4 P27487 1/20 0.40
FABP3 P05413 1/20 0.38
FABP4 P15090 1/20 0.38
ALDH1A1 P00352 2/20 0.35
MAPT P10636 1/20 0.35
HCAR3 P49019 1/20 0.35
KMT2A Q03164 2/20 0.35
GAA P10253 2/20 0.34
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
TSHR P16473 1/20 0.34
NR3C1 P04150 1/20 0.34
HDAC1 Q13547 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
RXRA P19793 3/20 0.32
RXRB P28702 1/20 0.32
RXRG P48443 1/20 0.32
NPC1 O15118 3/20 0.32
RAB9A P51151 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2428088 0.70 EGLN1 (0.43) EGLN1DPP4ALDH1A1MAPTKMT2A
SCHEMBL5364755 0.70 FABP3 (0.38) FABP3FABP4GAAKDM4EACE2
SCHEMBL15808993 0.68 EGLN1 (0.43) EGLN1DPP4FABP3FABP4ALDH1A1
SCHEMBL23809294 0.67 KDM4E (0.37) MAPTKMT2AKDM4ETSHRRAB9A
SCHEMBL23809195 0.67 NR3C1 (0.39) EGLN1FABP3FABP4ALDH1A1MAPT
SCHEMBL31160139 0.67 PRNP (0.41) EGLN1DPP4ALDH1A1MAPTKMT2A
SCHEMBL6124114 0.66 IKBKB (0.33) ALDH1A1KMT2AGAAKDM4EGLA
SCHEMBL22349081 0.66 ALDH1A1 (0.38) EGLN1DPP4ALDH1A1MAPTKMT2A
SCHEMBL9249253 0.65 FABP3 (0.50) DPP4FABP3FABP4GAATSHR
SCHEMBL22704842 0.65 DPP4 (0.40) EGLN1DPP4ALDH1A1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291621-B2 Substituted biaryl amides C5a receptor modulators NEUROGEN CORPORATION (US) 2007-11-06 US disclosed
US-6858637-B2 Treating rheumatoid arthritis, psoriasis, cardiovascular disease, reperfusion injury, and bronchial asthma; e.g., 2-Methoxynaphthalene-1-carboxylic acid benzyl-indan-2-yl-amide NEUROGEN CORPORATION (US) 2005-02-22 US disclosed
US-20040048913-A1 Substituted biaryl amides as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2004-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048913-A1 Substituted biaryl amides as C5a receptor modulators C5AR1, C5AR2, C3AR1 EGLN1 1427/4885DPP4 3236/4885FABP3 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.